Skip to main content

Table 1 Patient characteristics

From: CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'

  Baseline 6 months
DAS28CRP 5.7 (5.1-6.5) 2.1 (1.8-2.8)
Swollen joint count (0-28) 10 (7.0-17) 0 (0-0)
Tender joint count (0-28) 12 (7.0-18) 0 (0-1.3)
Swollen joint count (0-40) 13 (9.0-22) 0 (0-0)
Tender joint count (0-40) 17 (11-26) 0 (0-3.0)
VAS doctor global (0-100 mm) 56 (41-73) 2.0 (0-10)
CRP (mg/ml) 15 (7.0-42) 7.0 (7.0-7.0)
SDAI (0.7-82) 37 (29-47) 3.1 (0.86-7.0)
IgM-RF (% positive) 70.7% -
Anti-CCP (% positive) 62.7% -
TSS (% positive) 17.3% -
  1. Relevant disease markers at baseline and following 6 months of treatment. Data are expressed as median with interquartile range (IQR). Anti-CCP: anti-citrullinated protein antibody; CRP: C-reactive protein; DAS28CRP: disease activity in 28 joints, four variables, C-reactive protein based; IgM-RF: IgM rheumatic factor; SDAI: simple disease activity index; TSS: total Sharp score; VAS: visual analog scale.